Royalty Report: Medical, Drugs, Disease – Collection: 28057


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Drugs
  • Disease
  • Personal Care Products
  • Device
  • Monitoring
  • Supply
  • Therapeutic
  • Wound Care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28057

License Grant
This German company that reorganized and incorporated in Colorado has an agreement with the company’s CEO and CFO, pursuant to which he is entitled to royalties of gross revenues earned with any product based on his inventions.  The CEO founded the company and most of its products are based upon his research.
License Property
Their two long term projects are as follows  the development of a haemoglobin based artificial oxygen carrier to be used as a life-saving blood additive in all cases of severe deficiencies of oxygen supply (e.g. as aligned with stroke, heart attack, lung shock etc.), and the development of an implantable glucose sensor based on photometric measurement helping diabetes patients to easily and continuously monitor their glucose level, hence improving their insulin and creating a better quality of life.

Current products are as follows Pure Mo2isture, an anti-aging cosmetic skin care product based on an innovative micro-emulsion, Hemo2spray. Based on the company's expertise in the field of artificial oxygen carriers, this haemoglobin spray facilitates oxygen diffusion from outside to the superficial cells of the wound ground, – a product which will eventually feature a new quality in the treatment of chronic wounds, Chitoskin wound pads, demonstrating in all phases of wound healing not only the desired physical characteristics but also most favorable biological effects thus accelerating and enhancing the patients recovery.

Field of Use
The company claims to have innovations for the biological regeneration of cells through compensatory supply of vital substrates to the human body.

IPSCIO Record ID: 144368

License Grant
The Licensor,  an individual, an Executive Director and substantial shareholder of the Company, has licensed the rights to the Company.
License Property
Licensor is instrumental and has expertise in the development of oxygen carrier and glucose sensor.

The artificial extracellular oxygen carriers are capable of human organ support in cases of acute and chronic lack of oxygen or blood loss due to surgery, accident, arterial occlusion, anemia or other causes.

The implantable glucose sensor is for day and night monitoring of a patients glucose level.

Field of Use
The Licensee is in the business of developing hemoglobin based artificial oxygen carriers as blood volume substitutes and blood additive and by products thereof.  The Licensees products include those for use in anesthesia and sleep diagnostics and a skin-oxy-meter for determination of the oxygen supply and conductivity of the skin.

IPSCIO Record ID: 3180

License Grant
In this agreement, the Licensor established a joint venture company with a German Company, the entity is the Licensee.

The Licensor has granted the Licensee global distribution rights in this regard.

This new enterprise is charged with obtaining the CE mark certification authorizing the distribution of the Hemospray wound spray in the member states of the European Union.

License Property
Hemospray Wound Spray

The Licensor has developed a novel medical product aimed at the healing of chronic wounds. Chronic wounds are a medical problem of increasing importance as they originate from widespread risk factors such as diabetes, obesity, smoking etc. Lack of oxygen supply to the cells in the wound ground is the main reason why those wounds lose their genuine healing power. Based on its concept of artificial oxygen carriers, our Hemospray wound spray product bridges the watery wound surface and permits an enhanced afflux of oxygen to the wound ground.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.